Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
August 12 2022 - 7:30AM
Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a
biotechnology company focused on discovering, developing, and
commercializing novel gene therapies, biologicals, and vaccines,
announced that Dr. Shankar Musunuri, Chairman, Chief Executive
Officer and Co-Founder of Ocugen, will deliver a virtual
presentation at the H.C. Wainwright 2nd Annual Ophthalmology
Virtual Conference on August 17.
A video webcast of the presentation will be available on demand
beginning at 7:00 a.m. ET on August 17, 2022 for those registered
for the event and will be available on the events page of the
Ocugen investor site. The webcast replay will be archived for 90
days following the event.
About Ocugen, Inc.Ocugen, Inc. is a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies and vaccines that
improve health and offer hope for patients across the globe. We are
making an impact on patient’s lives through courageous
innovation—forging new scientific paths that harness our unique
intellectual and human capital. Our breakthrough modifier gene
therapy platform has the potential to treat multiple retinal
diseases with a single product, and we are advancing research in
infectious diseases to support public health and orthopedic
diseases to address unmet medical needs. Discover more at
www.ocugen.com and follow us on Twitter and
LinkedIn.Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should,” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks, and
uncertainties that may cause actual events or results to differ
materially from our current expectations. These and other risks and
uncertainties are more fully described in our periodic filings with
the Securities and Exchange Commission (SEC), including the risk
factors described in the section entitled “Risk Factors” in the
quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events, or otherwise, after the date of this
press release.
Contact:Tiffany HamiltonHead of
CommunicationsIR@ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Sep 2023 to Sep 2024